Prescribing information links can be found at the bottom of this page

Not all single inhaler triple therapies are the same.

Trelegy Ellipta is the only triple therapy for COPD to contain Fluticasone Furoate (ICS), Umeclidinium(LAMA) and Vilanterol (LABA) in one device.1 Three molecules that are engineered to last.2-12 Trelegy Ellipta delivers sustained efficacy in the once-daily, easy-to-use Ellipta device.1,13,19-21

Fluticasone furoate and vilanterol are not licensed as monotherapies in COPD.

*The clinical significance of in vitro data is not known. Systemic exposure assessed when FF administered as FF/VI by inhalation in patients with COPD.

The art of drug design

David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of Trelegy Ellipta are engineered to last.2-12 Trelegy Ellipta is designed to provide sustained efficacy for patients with COPD.1,13

The art of drug design

David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of Trelegy Ellipta are engineered to last.2-12 Trelegy Ellipta is designed to provide sustained efficacy for patients with COPD.1,13

The art of drug design

David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of Trelegy Ellipta are engineered to last.2-12 Trelegy Ellipta is designed to provide sustained efficacy for patients with COPD.1,13

How do the three licensed COPD components/combinations in Trelegy compare to products in their respective classes?

Trelegy Ellipta is the only triple therapy with in-class superiority data for its three COPD licensed components / combinations14-18

na

*Analysis based on a subset of patients whose randomisation stratum and pre-randomisation treatment included an ICS and a LABA. Patients could receive a LAMA throughout the treatment period in addition to their randomised treatment.
Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy15
Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.

What does this mean for your patients?

Trelegy Ellipta has been intentionally designed to provide your patients with sustained efficacy in the once-daily easy-to-use Ellipta device.1,13,19-21

Footnotes

ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist.

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA¹

Trelegy Ellipta is generally well tolerated. Common adverse reactions include: headache, nasopharyngitis, influenza, upper respiratory tract infection, pneumonia, back pain, rhinitis, cough, pharyngitis, arthralgia, sinusitis, oropharyngeal pain, bronchitis, constipation, candidiasis of mouth and throat, urinary tract infection.¹ This is not an exhaustive list. Please consult the Summary of Product Characteristics for a full list of adverse reactions before prescribing.

In common with other corticosteroid-containing medicines, there is an increased risk of pneumonia in patients with COPD treated with Trelegy Ellipta.¹

References:

  1. Trelegy Ellipta SmPC.
  2. Biggadike K et al. J Med Chem 2008; 51: 3349-3352
  3. Rossios et al. European Journal of Pharmacology 2011 670: 244–251
  4. Boscia et al. Clinical Therapeutics 2012; 34(8): 1655-1666
  5. Biggadike K et al. Clinical Therapeutics 2012; 34(8): 1655-1666
  6. Incruse Ellipta (umeclidinium bromide) SmPC.
  7. Laine DI et al. J Med Chem 2009; 52:2493-2505
  8. Salmon M et al. J of Pharm. & Exp. Ther. 2013; 345:260-270
  9. Feldman G et al. nt J Chron Obstruct Pulmon Dis 2016; 11:719–730.
  10. Slack RJ et al. J Pharmacol Exp Ther 2013; 344:218–230.
  11. Hanania NA; CHEST; 2012;142;119-127
  12. Kempsford et al. Pulm Pharmacol Ther. 2013; 26(2): 256-64
  13. Lipson DA Adv Ther 2020; 37;4894-4909
  14. Vestbo J et al. N Engl J Med 2016; 375:1253-60
  15. Relvar Ellipta SmPC
  16. Maltais F et al. Adv Ther 2019;36:2434-2449
  17. Feldman GJ et al. Adv Ther 2017; 34:2518-2533
  18. Feldman GJ et al. Int J Chron Obstruct Pulmon Dis 2016;11:719-730
  19. Svedsater H et al. BMC Pulm Med 2013; 13:1–14.
  20. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
  21. Riley JH et al. Int J Chron Obstruct Pulm Dis 2016; 11:1873– 1880.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

© 2021 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
Trelegy Ellipta was developed in collaboration with

PM-GB-FVU-WCNT-210007 | June 2021